Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

(2010) Yazdi K. Pithavala et al.   INVESTIGATIONAL NEW DRUGS

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

(2009) S. Sharma et al.   ANNALS OF ONCOLOGY

Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients

(2009) Zyting Chu et al.   ANTI-CANCER DRUGS

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

(2009) Y. K. Pithavala et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

(2009) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study

(2009) Joan H. Schiller et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients

(2008) Jürgen B. Bulitta et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

(2008) D. D. Hu-Lowe et al.   CLINICAL CANCER RESEARCH

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

(2008) Jean-Philippe Spano et al.   LANCET